# FDA 483 - Sunrise Pharmaceutical, Inc. - March 31, 2026

Source: https://www.keypedia.com/records/483/sunrise-pharmaceutical-inc/7fd5e1b5-74de-4caa-81dc-c80c5e6352b4

> FDA 483 for Sunrise Pharmaceutical, Inc. on March 31, 2026. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Sunrise Pharmaceutical, Inc.
- Inspection Date: 2026-03-31
- Product Type: drugs
- Office Name: New Jersey District Office
- Summary: An FDA inspection of Sunrise Pharmaceutical, Inc. in Rahway, NJ, identified a critical issue regarding the storage of drug products. The firm failed to store products under appropriate temperature conditions, lacking scientific rationale and comprehensive seasonal mapping for warehouse temperature monitoring. This deficiency could compromise the identity, strength, quality, and purity of their drug products.

## Related Documents

- [483 - 2018-01-18](https://www.keypedia.com/records/483/sunrise-pharmaceutical-inc/4159c34f-3efa-482e-9f9e-dc63c25cccb2)

## Related Officers

- [Alisha B. Patel](https://www.keypedia.com/people/alisha-b-patel/3c106dac-0e0d-41f2-9f7a-69982d4e6579)

Company: https://www.keypedia.com/companies/sunrise-pharmaceutical-inc/3e90c0a2-44c0-46f7-a6ff-ee1377824088

Office: https://www.keypedia.com/offices/new-jersey-district-office/6ff5e2e9-5cff-44c7-af24-5a55329a8248